Pharmacology of bisphosphonates

Bone

Volumn 49, Issue 1, 2011, Pages 42-49

  Cremers, Serge ^a   Papapoulos, Socrates ^b  

^a NewYork Presbyterian Hospital   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bisphosphonates; Pharmacodynamics; Pharmacokinetics; Review

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; GENERIC DRUG; IBANDRONIC ACID; INCADRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

AREA UNDER THE CURVE; BONE CANCER; BONE DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG INFORMATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; HUMAN; HYPERCALCEMIA; LOW DRUG DOSE; METABOLIC BONE DISEASE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PHARMACODYNAMICS; PHARMACOKINETICS; POSTMENOPAUSE OSTEOPOROSIS; QUANTITATIVE ANALYSIS; REVIEW; SINGLE DRUG DOSE;

ABSORPTION; ANIMALS; BONE AND BONES; DIPHOSPHONATES; HUMANS; TISSUE DISTRIBUTION;

EID: 79958750213     PISSN: 87563282     EISSN: 87563282     Source Type: Journal    
DOI: 10.1016/j.bone.2011.01.014     Document Type: Review

References (65)

1. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996, 18(2):75-85.
2. Cremers S.C., Pillai G., Papapoulos S.E. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005, 44(6):551-570.
3. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19(6):733-759.
4. Porras A.G., Holland S.D., Gertz B.J. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999, 36(5):315-328.
5. Dunn C.J., Goa K.L. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease. Drugs 2001, 61(5):685-712.
6. Gertz B.J., Holland S.D., Kline W.F., Matuszewski B.K., Freeman A., Quan H., et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995, 58(3):288-298.
7. Cheung W.K., Honc F., Schoenfeld S., Knight R., Seaman J., Bowen A.T., et al. A single-dose bioavailability study of pamidronate disodium after oral administration as encapsulated enteric-coated pellets, enteric-coated tablets, and a solution to patients with postmenopausal osteoporosis. Am J Ther 1994, 1(3):221-227.
8. Epstein S., Cryer B., Ragi S., Zanchetta J.R., Walliser J., Chow J., et al. Disintegration/dissolution profiles of copies of Fosamax (alendronate). Curr Med Res Opin 2003, 19(8):781-789.
9. Dansereau R.J., Crail D.J., Perkins A.C. In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70mg) and in vivo implications. Curr Med Res Opin 2008, 24(4):1137-1145.
10. Bioequivalence testing in the U.S. for generic drug products http://www.fda.gov/downloads/Drugs/NewsEvents/UCM182556.pdf.
11. Use of generic alendronate in the treatment of osteoporosis. S Afr Med J 2006, 96(8):696-697.
12. Ringe J.D., Moller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 2009, 30(2):213-221.
13. Grima D.T., Papaioannou A., Airia P., Ioannidis G., Adachi J.D. Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study. BMC Musculoskelet Disord 2010, 11:68.
14. Sheehy O., Kindundu C.M., Barbeau M., LeLorier J. Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int 2009, 20(8):1369-1376.
15. Halkin H., Dushenat M., Silverman B., Shalev V., Loebstein R., Lomnicky Y., et al. Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. Ann Pharmacother 2007, 41(1):29-34.
16. Monkkonen J., Koponen H.M., Ylitalo P. Comparison of the distribution of three bisphosphonates in mice. Pharmacol Toxicol 1990, 66(4):294-298.
17. Daubine F., Le Gall C., Gasser J., Green J., Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007, 99(4):322-330.
18. Lawson M.A., Xia Z., Barnett B.L., Triffitt J.T., Phipps R.J., Dunford J.E., et al. Differences between bisphosphonates in binding affinities for hydroxyapatite. J Biomed Mater Res B Appl Biomater 2010, 92(1):149-155.
19. van Beek E.R., Lowik C.W., Ebetino F.H., Papapoulos S.E. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone 1998, 23(5):437-442.
20. Jahnke W., Henry C. An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem 2010, 5(5):770-776.
21. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38(5):617-627.
22. Israel O., Front D., Hardoff R., Ish-Shalom S., Jerushalmi J., Kolodny G.M. In vivo SPECT quantitation of bone metabolism in hyperparathyroidism and thyrotoxicosis. J Nucl Med 1991, 32(6):1157-1161.
23. Carnevale V., Dicembrino F., Frusciante V., Chiodini I., Minisola S., Scillitani A. Different patterns of global and regional skeletal uptake of 99mTc-methylene diphosphonate with age: relevance to the pathogenesis of bone loss. J Nucl Med 2000, 41(9):1478-1483.
24. Weiss H.M., Pfaar U., Schweitzer A., Wiegand H., Skerjanec A., Schran H. Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos 2008, 36(10):2043-2049.
25. Masarachia P., Weinreb M., Balena R., Rodan G.A. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996, 19(3):281-290.
26. Azuma Y., Sato H., Oue Y., Okabe K., Ohta T., Tsuchimoto M., et al. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 1995, 16(2):235-245.
27. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991, 88(6):2095-2105.
28. Fogelman I., Bessent R.G., Turner J.G., Citrin D.L., Boyle I.T., Greig W.R. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med 1978, 19(3):270-275.
29. Hyldstrup L., Mogensen N., Jensen G.F., McNair P., Transbol I. Urinary 99m-Tc-diphosphonate excretion as a simple method to quantify bone metabolism. Scand J Clin Lab Invest 1984, 44(2):105-109.
30. Cremers S.C., Eekhoff M.E., Den Hartigh J., Hamdy N.A., Vermeij P., Papapoulos S.E. Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone. J Bone Miner Res 2003, 18(5):868-875.
31. Cremers S., Sparidans R., den H.J., Hamdy N., Vermeij P., Papapoulos S. A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol 2002, 57(12):883-890.
32. Cremers S.C., Papapoulos S.E., Gelderblom H., Seynaeve C., den Hartigh J., Vermeij P., et al. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. J Bone Miner Res 2005, 20(9):1543-1547.
33. Chen T., Berenson J., Vescio R., Swift R., Gilchick A., Goodin S., et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002, 42(11):1228-1236.
34. Roelofs A.J., Coxon F.P., Ebetino F.H., Lundy M.W., Henneman Z.J., Nancollas G.H., et al. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2010, 25(3):606-616.
35. Ebetino F.H., Roelofs A., Boyde A., Lundy M., McKenna C., Blazewska K., et al. Analyzing the skeletal distribution and cellular uptake of fluorescently-labeled bisphosphonate analogues in vivo. J Bone Miner Res 2009, (ASBMR annual meeting):Abstract FR0405.
36. Frith J.C., Monkkonen J., Blackburn G.M., Russell R.G., Rogers M.J. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997, 12(9):1358-1367.
37. Berenson J.R., Rosen L., Vescio R., Lau H.S., Woo M., Sioufi A., et al. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997, 37(4):285-290.
38. Mitchell D.Y., St Peter J.V., Eusebio R.A., Pallone K.A., Kelly S.C., Russell D.A., et al. Effect of renal function on risedronate pharmacokinetics after a single oral dose. Br J Clin Pharmacol 2000, 49(3):215-222.
39. Saha H., Castren-Kortekangas P., Ojanen S., Juhakoski A., Tuominen J., Tokola O., et al. Pharmacokinetics of clodronate in renal failure. J Bone Miner Res 1994, 9(12):1953-1958.
40. Skerjanec A., Berenson J., Hsu C., Major P., Miller W.H., Ravera C., et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003, 43(2):154-162.
41. Body J.J., Diel I., Bell R. Profiling the safety and tolerability of bisphosphonates. Semin Oncol 2004, 31(5 Suppl 10):73-78.
42. Drake M.T., Cremers S.C. Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition. Mol Interv 2010, 10(3):141-152.
43. Khan S.A., Kanis J.A., Vasikaran S., Kline W.F., Matuszewski B.K., McCloskey E.V., et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997, 12(10):1700-1707.
44. Kasting G.B., Francis M.D. Retention of etidronate in human, dog, and rat. J Bone Miner Res 1992, 7(5):513-522.
45. Papapoulos S.E., Cremers S.C. Prolonged bisphosphonate release after treatment in children. N Engl J Med 2007, 356(10):1075-1076.
46. Phipps R., LR, Burgio D., et al. Head-to-head comparison of risedronate and alendronate pharmacokinetics at clinical doses. Bone 2004, 34:S81-S82.
47. Papapoulos S.E., Hoekman K., Lowik C.W., Vermeij P., Bijvoet O.L. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J Bone Miner Res 1989, 4(5):775-781.
48. van Beek E., Pieterman E., Cohen L., Lowik C., Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 1999, 255(2):491-494.
49. Rosen C.J., Hochberg M.C., Bonnick S.L., McClung M., Miller P., Broy S., et al. Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005, 20(1):141-151.
50. Gasser J.A., Ingold P., Venturiere A., Shen V., Green J.R. Long-term protective effects of zoledronic acid on cancellous and cortical bone in the ovariectomized rat. J Bone Miner Res 2008, 23(4):544-551.
51. Grey A., Bolland M.J., Wattie D., Horne A., Gamble G., Reid I.R. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 2009, 94(2):538-544.
52. Caldwell G.W., Masucci J.A., Yan Z., Hageman W. Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data?. Eur J Drug Metab Pharmacokinet 2004, 29(2):133-143.
53. Booth B., RA, Ibrahim A., et al. A population pharmacokinetic model for zoledronic acid (ZOMETA) in patients with bone metastases. Am Soc Clin Pharmacol Ther 2003, 67. [P-III-20].
54. Pillai G., Gieschke R., Goggin T., Jacqmin P., Schimmer R.C., Steimer J.L. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br J Clin Pharmacol 2004, 58(6):618-631.
55. Ohno Y., Yamada Y., Usu T., Takahashi K., Tsuchiya F., Ohtani H., et al. Pharmacokinetic and pharmacodynamic analysis of the antihypercalcemic effect of incadronate disodium in rats. Biol Pharm Bull 2001, 24(11):1290-1293.
56. Pillai G., Gieschke R., Goggin T., Barrett J., Worth E., Steimer J.L. Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females. Int J Clin Pharmacol Ther 2006, 44(12):655-667.
57. Wright P.M. Population based pharmacokinetic analysis: why do we need it; what is it; and what has it told us about anaesthetics?. Br J Anaesth 1998, 80(4):488-501.
58. Zaidi M., Epstein S., Friend K. Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans. Ann NY Acad Sci 2006, 1068:560-563.
59. Bauss F., Russell R.G. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004, 15(6):423-433.
60. Watts N.B., Chines A., Olszynski W.P., McKeever C.D., McClung M.R., Zhou X., et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2008, 19(3):365-372.
61. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004, 350(12):1189-1199.
62. Coleman R.E., Major P., Lipton A., Brown J.E., Lee K.A., Smith M., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005, 23(22):4925-4935.
63. Peterson M.C., Riggs M.M. A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. Bone 2010, 46(1):49-63.
64. Keaveny T.M., Donley D.W., Hoffmann P.F., Mitlak B.H., Glass E.V., San Martin J.A. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 2007, 22(1):149-157.
65. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354(8):821-831.